In This Article:
As the U.S. equities market starts the new year with a continued slump, investors are closely monitoring opportunities that might emerge amidst broader market challenges. Penny stocks, often representing smaller or newer companies, remain an intriguing niche for those seeking growth potential beyond the well-trodden paths of large-cap investments. Despite their vintage name, these stocks can still offer surprising value and stability when backed by solid financial foundations.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
Inter & Co (NasdaqGS:INTR) | $4.11 | $1.85B | ★★★★☆☆ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $110.4M | ★★★★★★ |
BAB (OTCPK:BABB) | $0.838 | $5.59M | ★★★★★★ |
Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.58 | $9.9M | ★★★★★★ |
ZTEST Electronics (OTCPK:ZTST.F) | $0.3267 | $10.67M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
BTCS (NasdaqCM:BTCS) | $2.62 | $42.86M | ★★★★★★ |
Smith Micro Software (NasdaqCM:SMSI) | $1.45 | $23.24M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $1.01 | $84.54M | ★★★★★☆ |
Safe Bulkers (NYSE:SB) | $3.66 | $381.2M | ★★★★☆☆ |
Click here to see the full list of 727 stocks from our US Penny Stocks screener.
Let's uncover some gems from our specialized screener.
AC Immune
Simply Wall St Financial Health Rating: ★★★★★★
Overview: AC Immune SA is a clinical stage biopharmaceutical company focused on discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases linked to protein misfolding, with a market cap of $267.14 million.
Operations: No revenue segments have been reported for this clinical stage biopharmaceutical company.
Market Cap: $267.14M
AC Immune, a clinical-stage biopharmaceutical company with a market cap of US$267.14 million, is pre-revenue and primarily focused on neurodegenerative diseases. Recent developments include promising interim safety data from trials targeting Alzheimer's and Parkinson's diseases, with ACI-24.060 receiving Fast Track designation from the FDA. The company's financials show CHF 25.49 million in third-quarter revenue and positive net income after previous losses. Despite being unprofitable overall, AC Immune benefits from strong short-term asset coverage over liabilities and no debt, providing a cash runway exceeding three years if current conditions persist.
-
Jump into the full analysis health report here for a deeper understanding of AC Immune.
-
Examine AC Immune's earnings growth report to understand how analysts expect it to perform.
Orchestra BioMed Holdings
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Orchestra BioMed Holdings, Inc. is a biomedical innovation company with a market cap of $152.05 million.